Recent Revenue Shift Xtant Medical's revenue for Q1 2026 was $20.9 million, down from $32.9 million a year earlier due to asset sales and non-repeating license revenue. Opportunities may lie in cross-selling remaining orthobiologics, spinal implants, and wound care products to existing customers and expanding international sales.

Asset divestitures The July 2025 sale of Coflex and CoFix assets and related Paradigm Spine business indicates a refocus on core technologies. This creates potential for upsell of core spine and orthopedic biologics, as well as opportunities to license or partner on remaining product lines with new market access.

New product launches Introduction of Trivium Shaped allograft and nanOss Strata synthetic bone graft positions Xtant in bone regeneration and grafting solutions. Sales teams can target orthopedic and neurosurgical practices seeking advanced grafts and wound closure products to differentiate from competitors.

Strategic partnerships Recent collaborations for donor and tissue initiatives with Montana state programs and participation in industry conferences signal a focus on stakeholder engagement and education. Leverage these partnerships to expand adoption through case studies, CME-style trainings, and hospital procurement pathways.

Market expansion readiness Despite reduced revenue in 2025 due to divestitures, the company remains a global player with a diverse product line in spinal, orthopedic, and biologics. Identify international hospitals and distributors seeking integrated surgical solutions that combine implants, biologics, and grafting technology to capture share in growth markets.